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Abstract
Background: Endothelial-specific knockout of the transcription factor serum response factor (SRF) results in
embryonic lethality by mid-gestation. The associated phenotype exhibits vascular failure in embryos as well as
visceral yolk sac (VYS) tissues. Previous data suggest that this vascular failure is caused by alterations in cell-cell and
cell-matrix contacts. In the current study, we sought to more carefully address the role of SRF in endothelial
function and cell contact interactions in VYS tissues.
Results: Tie2-Cre recombinase-mediated knockout of SRF expression resulted in loss of detectable SRF from VYS
mesoderm by E12.5. This loss was accompanied by decreased expression of smooth muscle alpha-actin as well as
vascular endothelial cadherin and claudin 5, endothelial-specific components of adherens and tight junctions,
respectively. Focal adhesion (FA) integrins alpha5 and beta1 were largely unchanged in contrast to loss of the FA-
associated molecule vinculin. The integrin binding partner fibronectin-1 was also profoundly decreased in the
extracellular matrix, indicating another aspect of impaired adhesive function and integrin signaling. Additionally,
cells in SRF-null VYS mesoderm failed to reduce proliferation, suggesting not only that integrin-mediated contact
inhibition is impaired but also that SRF protein is not required for proliferation in these cells.
Conclusions: Our data support a model in which SRF is critical in maintaining functional cell-cell and cell-matrix
adhesion in endothelial cells. Furthermore, we provide evidence that supports a model in which loss of SRF
protein results in a sustained proliferation defect due in part to failed integrin signaling.
Background
Serum response factor (SRF) is a member of the MADS
(MCM1, Agamous, Deficiens, SRF) family of nuclear
transcription factors. SRF acts as a dimer to recognize
the serum response element (SRE), a ten base pair AT-
rich sequence (CC(AT)6 GG), also referred to as the
CArG box [1,2]. The SRE binding sequence is found in
a diverse array of genes including cellular immediate
early genes (IEGs), neuronal nuclear receptors, and
cytoskeletal and contractile proteins. The specificity of
SRF regulatory actions is context dependent and relies
on combinatorial interactions between SRF and various
accessory factors. The Elk-1 and SAP-1 Ets family
members, which form nuclear complexes with SRF, are
direct targets for mitogen activated kinase (MAPK)
phosphorylation. Also, the myocardin family of SRF-
interacting proteins (MRTFs) are important for regulat-
ing transcriptional targets associated with Rho-mediated
actin polymerization [3].
SRF is a central regulator of myogenic gene expres-
sion, cell differentiation and function. It is robustly
expressed in cells of myogenic lineage [4-6], and
required for differentiation and development of skeletal
myoblasts [7,8], cardiomyocytes [9,10] and smooth mus-
cle cells (SMC) [1,11,12]. The expression and regulation
of muscle cell contractile proteins depend on SRF tran-
scriptional control [13,14], and SRF has been shown to
provide a direct link between alterations in actin
dynamics and consequential changes in nuclear tran-
scription (reviewed in [15]. The G-actin associated pro-
tein MAL (a.k.a. myocardin-related transcription factor-
4, MRTF-4) is released from monomeric actin upon
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released, MAL translocates to the nucleus and interacts
with SRF to mediate gene transcription of cytoskeletal
apparatus proteins such as vinculin, actins, myosin, and
focal adhesion (FA) molecules as well as SRF itself
[16,17].
SRF has also been implicated as an important regula-
tor of numerous events during early development.
Embryos globally lacking SRF are unable to generate the
embryonic mesoderm germ layer and die during gastru-
lation [18]. Tissue specific deletions of the Srf gene
show it is essential for vascular SMC differentiation
(reviewed in [12] and cardiogenesis [9,19,20]. SRF is also
important for development of brain cells [21,22],
immune cells [23] and skin epithelium [24]. A require-
ment for SRF in early vasculogenesis has been demon-
s t r a t e db yv i r t u eo fi t si m p o r t a n c ea sar e g u l a t o ro f
SMC gene expression. In avian systems, SRF is required
for differentiation of coronary SMC from progenitors
within the proepicardium, a transient embryonic struc-
ture that contributes to coronary vasculogenesis [25,26].
SRF and other members of the MADS-box family
have also been shown to regulate cell growth and prolif-
eration in numerous cell types, including rat embryonic
fibroblasts [27], myoblasts [28], and gut and liver tissues
[29]. While the precise mechanism by which SRF con-
trols proliferation is not known, it has been demon-
strated that activated MAPK phosphorylates a nuclear
complex containing SRF and Ets/TCFs to induce expres-
sion of the IEG c-fos [30,31]. Therefore, it is likely that
SRF is at least critical for MAPK-mediated cellular pro-
liferation where it acts to mediate cellular IEG expres-
sion and enable the G0 to G1 cell cycle transition
[30-33]. SRF is also important for proper cellular adhe-
sion. In particular, several proteins associated with
integrin-fibronectin signaling at FA are known SRF-tar-
get genes; among them are integrins a1, a5, a9, b1,
talin 1, vinculin, and syndecans 2 and 4 [14]. Matrix
metalloproteinase 9 (MMP9) is also potentially regulated
by SRF [15]. MMP9, together with MMP2, is responsible
for degradation of fibronectin and other ECM proteins,
suggesting SRF plays a role in the modulation of extra-
cellular matrix (ECM) deposition and maintenance as
well.
While SRF has been established as a critical regulator
of myogenic cells, relatively little is known about the
role of SRF in vascular endothelial cells (VEC). Chai and
colleagues [34] showed that SRF is required for appro-
priate vascular endothelial growth factor (VEGF)-depen-
dent signaling in endothelial cells in vitro, suggesting a
role for SRF in VEC function. More recent in vivo stu-
dies from our laboratory and others demonstrate that
SRF plays a critical role in endothelial cell function dur-
ing early vascular development in the mouse [35,36].
K n o c k o u to fS R Fe x p r e s s i o ni na ne n d o t h e l i a ls p e c i f i c
manner by either Tie2-Cre [36] or Tie1-Cre [35]
-mediated genomic recombination resulted in death by
embryonic day 13-14.5 (E13-E14.5). TIE2 is a tyrosine
kinase receptor expressed specifically on endothelial
cells where it acts to mediate angiopoietin signaling
[37]. Both studies suggest that the defect in SRF-null
VECs stems from dysfunctional cell-cell and cell-ECM
contacts. Lack of appropriate cell contacts could also
lead to inappropriate vascular permeability (e.g. ions,
solutes) as well as gross vascular damage, causing vascu-
lar failure and formation of microthrombi [38], which
are especially notable in the heart and body of VEC-spe-
cific SRF-null embryos [36]. We also observed severe
disruption of vascular integrity in visceral yolk sac
(VYS) tissues.
In the current study, we sought to characterize the
severe disruption of VYS vascular tissues observed in
VEC-specific SRF-null embryos. Mice homozygous for a
floxed Srf gene, Srf
f/f [39] were bred to mice expressing
Tie2-promoter driven Cre recombinase [40]. The result-
ing Tie2-Cre
+/0 Srf
f/f mutant genotype resulted in
embryonic lethality by E13.5. Analysis of Tie2-Cre con-
struct expression in mid-gestation VYS revealed wide-
spread contributions to VYS mesoderm tissue from
early progenitors. Adhesion molecule organization, cell-
cell and cell-matrix contacts, and various junction com-
plexes as well as actin dynamics associated with intracel-
lular signaling are disrupted throughout the VYS
mesoderm following the Tie2-Cre-mediated loss of SRF.
These results are consistent with previous studies sug-
gesting SRF plays a role in controling expression of
adhesion molecules and is involved with cell-matrix
associated signaling cascades. Additionally, we find that
SRF-null VYS mesoderm cells continue to proliferate
while wild-type tissues with unimpaired adhesive con-
tacts do not. These data suggest that perturbed signaling
through cell-cell and cell-matrix contacts results in a
loss of adhesion-dependent growth arrest. These data
also suggest that a non-SRF dependent mechanism such
as the Jak/STAT pathway may be responsible for prolif-
eration in VYS mesoderm. Consequently, SRF appears
to be vital for the formation and maintenance of adhe-
sive contacts but dispensable for proliferation during
angiogenic remodeling and vascular plexus maturation.
Results
Tie2-Cre-mediated loss of SRF is specific to VYS
mesoderm endothelial cells and is complete by E12.5
To establish the location and identity of cells in VYS
expressing the Tie2-Cre construct, indicating which cells
w o u l db et a r g e t e df o rSrf genomic recombination, we
bred male mice expressing the Tie2-Cre construct and
heterozygous for the floxed Srf allele (Tie2-Cre
+/0·Srf
f/+)
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and the ROSA26R-eYFP fluorescent reporter transgene
(Srf
f/f·ROSA26R-eYFP
+/+). This genetic combination
enabled us to track effective Tie2-Cre-mediated excision
by staining for eYFP expression, identifying cells in
which the floxed Srf gene had potentially undergone
recombination. Subsequent double-label immunofluores-
cence analysis of E12.5 VYS revealed that loss of detect-
able SRF protein was specific to cells with efficient
Tie2-Cre activity (see Figure 1A &1B). VYS mesoderm
cells expressing Tie2-Cre as shown by the presence of
eYFP protein contained no detectable levels of SRF in
contrast to comparable Tie2-Cre
-/- VYS tissues. eYFP
expression was observed throughout the VYS mesoderm
but not in VYS endoderm. Immunofluorescence detec-
tion of vascular endothelial cadherin (CDH5, a.k.a. VE-
Cad) demonstrated the endothelial identity of cells
within the VYS mesoderm (see Figure 1C &1D). Sepa-
rate studies using ROSA26R-b-galactosidase reporter
transgenic mice confirm the observed eYFP expression
pattern (see Additional File 1). For these experiments,
male Tie2-Cre
+/0 mice were bred with female ROSA26R-
bgal
+/+ mice; resulting VYS tissues were Lac-Z stained
to uncover Tie2-Cre-related b-galactosidase activity.
Lac-Z staining was evident in vascular tissues by E10.5;
by E12.5 staining was robust and widespread throughout
the VYS mesoderm but completely absent from VYS
endoderm. Taken together, these data demonstrate the
VYS mesoderm endothelial-specific expression of Tie2-
Cre.
The Tie2-Cre transgenic construct begins expressing
by E7.5 in early VYS in the mouse embryo [40]. This
timing coincides with the development of VYS blood
islands and onset of initial haematopoiesis [41]. Vascular
structures in VYS mature, and blood cell production
continues until haematopoiesis shifts to sites within the
embryo by E12.5. We previously showed that Tie2-Cre-
mediated loss of SRF results in embryo lethality by
E13.5 [36]. We showed that Tie2Cre
+/0·Srf
f/f embryos
appear normal until E10.5 but begin exhibiting evidence
of vascular failure and haemorrhaging by E11.5. This
becomes more pronounced by E12.5, and embryos are
dying or dead by E13.5. VYS tissues from these embryos
mirror the same timeframe of vascular disruption as
observed in the embryo. The Tie2-Cre construct begins
expression in VYS at E7.5, some days earlier than a
grossly observable phenotype at E11.5. We therefore
determined the timeline of SRF loss within the VYS
mesoderm by generating embryos using the breeding
scheme described above, and harvesting Tie2Cre
+/0·Srf
f/f
and wild-type littermate embryos at E10.5, E11.5, and
E12.5 for SRF expression analysis. We found that SRF
loss is complete in VYS mesoderm cells of Tie2Cre
+/0·Srf
f/f embryos by E12.5 (see Figure 2A &2B) despite
being detectable in both wild type and mutant tissues at
E10.5 and E11.5 (see Additional File 2). We counted
individual SRF-positive nuclei in VYS mesoderm from
Tie2Cre
+/0·Srf
f/f and wild-type littermate embryos, and
expressed the result as a percentage of total nuclei
detected (DAPI stain) (see Figure 2C). The number of
VYS mesoderm cells containing detectable levels of SRF
is significantly decreased at E10.5 (38 ± 2% WT vs. 15 ±
2% Tie2Cre
+/0·Srf
f/f;p=0 . 0 0 0 3 ) ,a sw e l la sa tE 1 1 . 5( 3 5
Figure 1 SRF protein is lost in VYS mesoderm endothelial cells
expressing Tie2-Cre recombinase. Double-label
immunofluorescence images of E12.5 VYS tissue from wild type
(Tie2Cre
-/-·Srf
f/f·ROSA26R-eYFP
+/+; A, C) and SRF-null (Tie2Cre
+/0·Srf
f/
f·ROSA26R-eYFP
+/+; B, D) embryos. (A, B) Immunostaining of eYFP by
anti-GFP antibody was used to detect evidence of functional Tie2-
Cre expression. Tissues in A & B were stained for SRF (green), GFP
(red), and DNA (blue). Arrows in A highlight SRF-positive nuclei in
VYS mesoderm; arrowheads in B highlight GFP positive cells in VYS
mesoderm. (C, D) VE-Cad labels endothelial cells in VYS mesoderm.
Tissues in C & D were stained for VE-Cad (red) and DNA (blue).
Arrow (C) and arrowheads (D) indicate positive VE-Cad staining.
Magnification = 200×, scale bars = 50 μm; Ed = endoderm, Md =
mesoderm.
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+/0·Srf
f/f; p = 0.0004) and
nearly absent from E12.5 Tie2Cre
+/0·Srf
f/f VYS meso-
derm (52 ± 13% WT vs. 1 ± 1% Tie2Cre
+/0·Srf
f/f;p=
0.00008). To establish that the lowered levels of SRF
protein were capable of affecting the expression of SRF-
dependent genes, tissues stained for SRF were also
stained for smooth muscle a-actin (ACTA2). ACTA2 is
a cytoskeletal protein dependent on SRF for expression
[42] and was not used as a marker for the presence of
smooth muscle cells. ACTA2 expression was detectable
in wild-type VYS mesoderm by E10.5 and remained so
through E12.5 (see Figure 2 and Additional File 2), but
appeared disrupted in E10.5 Tie2Cre
+/0·Srf
f/f VYS tissues.
Disruption of ACTA2 expression continued and wor-
sened in E11.5 and E12.5 Tie2Cre
+/0·Srf
f/f VYS
mesoderm.
Together the data presented in Figures 1 and 2
demonstrate that SRF protein is progressively lost from
E10.5 through E12.5, being largely or completely lost by
E12.5 in VYS mesoderm tissues of Tie2Cre
+/0·Srf
f/f
embryos. Complete loss of SRF protein is preceded by
detectable alterations in SRF-dependent proteins such as
ACTA2.
Alterations in cell contacts contribute to VYS failure
SRF has been demonstrated to be an important regula-
tor of cell shape, integrity, migration, and adhesion
(reviewed in [15]. Cytoskeletal elements rely on
interactions with the plasma membrane to transduce
extracellular signals generated by receptor ligands and
ECM proteins. We previously showed ultrastructural
evidence that loss of SRF in VYS tissues resulted in a
lack of cell-cell adhesion contacts and disrupted ECM
deposition [36]. Using electron microscopy analysis of
E12.5 VYS from Tie2Cre
+/0·Srf
f/f embryos, we found
cells in VYS mesoderm lacked appropriate cell-cell junc-
tions compared to wild-type littermate tissues. We also
observed deficient ECM deposition between mesoderm
and endoderm layers in these same tissues. Our obser-
vations are consistent with other studies that point to a
role for SRF in regulation of adhesion molecules.
Embryonic stem cells lacking SRF are unable to form
FAs or bind appropriately with different ECM compo-
nents [43]. Furthermore, expression of FA molecules
such as vinculin and tropomyosin is regulated by SRF
and MRTFs through a Rho/MAL-dependent mechanism
[17]. In the current study, we investigated the cause of
the observed loss of tissue integrity in VYS tissues,
focusing on the role of SRF in: 1) cell-cell contacts, 2)
cell-matrix contacts, and 3) ECM deposition.
To address potential changes in expression of adhe-
sion molecules and ECM in SRF-null VYS mesoderm
in more detail, we generated endothelial-specific SRF-
null embryos using the breeding scheme described
above and harvested Tie2Cre
+/0·Srf
f/f and wild-type lit-
termate embryos at E12.5 for analysis. We focused our
Figure 2 SRF protein loss is complete by E12.5 in Tie2Cre
+/0·Srf
f/f embryos. Double-label immunofluorescence images of VYS tissue from
wild type (A) and SRF-null (B) embryos at E12.5. Tissues were stained for SRF (green), ACTA2 (red), and DNA (blue). Arrows in A highlight SRF-
positive nuclei; arrowheads in B mark nuclei lacking SRF. Dashed line indicates division between Ed and Md layers. Magnification = 200×, scale
bar = 50 μm; Ed = endoderm, Md = mesoderm. See Additional File 2 for comparable immunofluorescence images from E10.5 and E11.5 tissues.
(C) Cytometric analysis of SRF-positive nuclei in E10.5, E11.5, and E12.5 VYS mesoderm cells. Values are expressed as a percentage of total DAPI-
stained nuclei counted. SRF protein loss is complete by E12.5. *p = 0.0003; **p = 0.0004; ***p = 0.00008.
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phenotype observed was most consistent by this devel-
opmental timepoint. We examined the EC-specific
adhesion molecule VE-Cad as a measure of appropriate
cell-cell contact. VE-Cad is a VEC-specific transmem-
brane adhesion protein associated with adherens junc-
tions (AJ) [44]. It forms homodimeric complexes
between adjacent cells and is expressed in all VECs
upon committed differentiation. Tie2Cre
+/0·Srf
f/f VYS
mesoderm tissues display decreased VE-Cad immunor-
eactivity compared to wild-type tissues (see Figure 1C
&1D). This result is consistent with our previous
observation of contact deficiencies at an ultrastructural
level between endothelial cells.
To address cell-matrix contact, we examined integrin
a5 (ITGA5, a.k.a. a5) expression. a5 is a member of the
integrin family of proteins that form heterodimeric com-
plexes composed of one alpha and one beta chain [45].
a5 pairs with integrin b1 (ITGB1, a.k.a. b1) to bind spe-
cifically to fibronectin-1 (FN1) in ECM and form cell-
matrix FAs. VECs express several integrin family mem-
bers, and global knockouts of either a5o rb1c a u s e
defective vascular development and embryonic lethality
[46,47]. However, recent studies examining VEC-specific
loss of a5 did not detect impaired vasculogenesis [48] in
contrast to VEC-specific ablation of b1t h a tr e s u l t si n
embryonic lethality [49]. Other studies suggest that the
Itga5 gene may be under SRF regulatory control as evi-
denced by the presence of an SRE within its promoter
[50]. We detected a5 protein at sites of cell-matrix
interactions in both wild type and Tie2Cre
+/0·Srf
f/f VYS
tissues (see Figure 3). We did not observe large changes
in a5 protein expression patterns despite the lack of
SRF protein observed in VYS tissues at this time, sug-
gesting that loss of cell-ECM contacts in SRF deficient
animals is due to another mechanism.
To address whether loss of SRF may affect signaling
associated with FAs, we examined vinculin (VCL)
expression. VCL is a membrane-associated protein
involved with linkage of b1 cytoplasmic tails to the actin
cytoskeleton [51]. It is important as a regulator of
mechanical stress between extracellular forces and intra-
cellular response through cytoskeletal dynamics. VCL
expression is dependent on SRF/MRTF-mediated tran-
scriptional regulation, and the Vcl gene is predicted to
contain an SRE within its promoter [50]. We examined
VCL protein expression patterns in VYS mesoderm by
immunofluorescence and found detectable protein in
both wild-type and SRF-null tissues at E10.5 (See Figure
4C &4D). However, by E12.5, VCL staining was moder-
ately disrupted in Tie2Cre
+/0·Srf
f/f compared to wild-type
tissues (see Figure 4A &4B). Disturbance of VCL stain-
ing was correlated with loss of SRF protein as shown by
double-label analysis.
Figure 3 ITGA5 is maintained despite loss of SRF expression.
Cell-ECM contacts occur at FA consisting of integrin proteins.
Double-label immunofluorescence images of VYS tissue from wild
type (A) and SRF-null (B) embryos at E12.5. Tissues were stained for
ITGA5 (green), ACTA2 (red), and DNA (blue). ACTA2 was used to
monitor SRF status in mesoderm due to antibody incompatibility
between anti-SRF and anti-ITGA5 antibodies. Arrows and
arrowheads highlight points of ITGA5 expression in VYS mesoderm
cells. Magnification = 200×, scale bar = 50 μm; Ed = endoderm, Md
= mesoderm.
Figure 4 VCL is moderately disrupted following loss of SRF. FA-
associated intracellular signaling requires VCL interactions between
integrins and the actin cytoskeleton. Double-label
immunofluorescence images of VYS tissue from wild type (A, C) and
SRF-null (B, D) embryos at E12.5 (A, B) and E10.5 (C, D). Tissues were
stained for SRF (green), VCL (red), and DNA (blue). Arrows/
arrowheads mark VCL protein. Magnification = 200×, scale bar = 50
μm; Ed = endoderm, Md = mesoderm.
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deposition we previously observed in Tie2Cre
+/0·Srf
f/f VYS
tissues, we assayed for the ECM component FN1. FN1 dis-
plays robust expression around developing vessels [52] and
induces intracellular signaling via interactions with the
FN1 receptor integrin pair a5b1 [45]. FN1 protein expres-
sion was visible in both wild-type and SRF-null VYS tis-
sues at E10.5 (see Figure 5C &5D). In contrast, Tie2Cre
+/0·Srf
f/f VYS tissues showed a profound decrease in
detectable FN1 compared to wild-type tissues at E12.5
(see Figure 5A &5B). Tissue sections were co-stained with
E-cadherin (CDH1, a.k.a. E-Cad) to demonstrate contact
deficient status of SRF-null tissues due to primary anti-
body incompatibility with the anti-SRF antibody.
Taken together, these data provide evidence that the
loss of SRF in VYS mesoderm results in disruption of
cell-cell and cell-ECM contacts. Decreased VE-Cad pro-
tein indicates that intercellular adhesion between EC is
disordered. Cell-ECM adhesion is also disturbed due to
a significant lack of ECM-associated FN1 despite appar-
ently unaffected levels of a5. Furthermore, the observed
decrease in VCL protein suggests that VCL-dependent
intracellular signaling cascades may be perturbed.
Gene expression analysis shows SRF-null VYS tissue is
contact deficient
To examine potential changes in gene transcription in
SRF-null VYS tissue, we assayed whole VYS from E12.5
Figure 5 ECM in Tie2Cre
+/0·Srf
f/f VYS tissue lacks FN1. FN1 contributes to ECM surrounding developing vessels and is critical for signaling in
VYS tissues. Double-label immunofluorescence images of VYS tissue from wild type (A, C) and SRF-null (B, D) embryos at E12.5 (A, B) and E10.5
(C, D). Tissues were stained for E-Cad (green), FN1 (red), and DNA (blue). Arrows/arrowheads mark FN1 expression. Magnification = 200×, scale
bar = 50 μm; Ed = endoderm, Md = mesoderm.
Figure 6 Adhesion molecule gene expression is disrupted in
SRF-null VYS tissues. Quantification of mRNA levels in whole VYS
tissues from wild type and Tie2Cre
+/0·Srf
f/f embryos. Fold change was
calculated using 2^ΔΔCt, where a value of ‘1’ indicates no change.
Bars represented as * indicate no signal was detected in samples
from Tie2Cre
+/0·Srf
f/f embryos. Values represent fold change with
positive SEM only. Genes listed: serum response factor (Srf), b-actin
(Actb), smooth muscle a-actin (Acta2), platelet-endothelial adhesion
molecule-1 (Pecam1), vascular endothelial cadherin (Cdh5, a.k.a. VE-
Cad), b-catenin (Ctnnb1), claudin 5 (Cldn5), tight junction protein 1
(Tjp1, a.k.a. ZO-1), integrin-a5( Itga5), integrin-b1( Itgb1), vinculin
(Vcl), fibronectin-1 (Fn1).
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Figure 6). Separation of mesoderm from endoderm in
Tie2Cre
+/0·Srf
f/f VYS was not feasible due to the fragile
nature of SRF-null VYS tissues. We focused our analysis
on genes involved in cellular adhesion that are either
known or predicted to be targets of SRF regulation as
well as those we found altered during our immunofluor-
escence studies. Results are expressed using the 2^ΔΔCt
method where a value of 1 indicates no difference
between groups. Srf expression was found to be
decreased (0.596) in Tie2Cre
+/0·Srf
f/f VYS tissue; message
in VYS endoderm not affected by Tie2-Cre-mediated
genomic excision may account for the message detected
given the lack of visible SRF signal in VYS mesoderm
identified by immunofluorescence. We found a trend
toward decreased expression of Acta2 (0.215). Our own
observations of virtually undetectable expression of
ACTA2 protein in SRF-null VYS (Figure 2) support pre-
viously reported observations that Acta2 expression is
SRF-dependent. AJ-associated VE-Cad (a.k.a. Cdh5)
expression was profoundly decreased (0.238), as was
expression of another EC-specific homophilic adhesion
molecule, Pecam1 (0.522). Expression of the intracellular
signaling molecule b-catenin (Ctnnb1)t h a tp a r t n e r s
with VE-Cad and PECAM1 proteins was not changed
(1.007). Expression of the EC-specific tight junction (TJ)
component claudin 5 (Cldn5) was not detectable in
mutant tissues, while expression of its associated intra-
cellular signaling molecule tight junction protein 1
(Tjp1, a.k.a. ZO1) was slightly increased (1.733). We
assayed Itga5 and Itgb1 expression as a measure of FA
assembly and found they were relatively unchanged
(1.283 and 1.077, respectively), consistent with our
observation of minimal change in a5p r o t e i n .I nc o n -
trast, Vcl expression was not detectable in mutant tis-
sues, suggesting that failure of FAs is due at least in
part to the lack of linkage between membrane-asso-
ciated integrins and the actin cytoskeleton. We did not
detect any evidence of integrin-linked kinase (Ilk)
expression in any tissue; Ilk qPCR primer specificity
was verified against HeLa cell cDNA (data not shown).
Furthermore, expression of Fn1 was decreased (0.436),
implying a lack of ECM substrate for binding of integ-
rins at the plasma membrane. Our immunofluores-
cence analysis demonstrating profound disruption of
both VCL and FN1 proteins corroborates these
changes in gene expression. Taken together, expression
analysis of the three pairs of junction related proteins
suggests a cumulative effect of adhesion failures, and
that cell-cell and cell-ECM contact deficiency and
impaired integrin signaling is at least partly responsible
for the vascular phenotype observed in Tie2Cre
+/0·Srf
f/f
embryos.
SRF is not required for proliferation of VYS mesoderm
cells
Consistent with a role for SRF in mediating growth fac-
tor signaling, it has been shown in a number of cell
t y p e st h a tl o s so fS R Fi n h i b i ts proliferation [53]. Cell
adhesion-associated signaling is intimately connected to
appropriate regulation of proliferation as well as other
functions such as migration and differentiation (for
review see [54]. These observations together with our
experimental results that loss of SRF leads to impaired
adhesion initially suggested to us that in SRF-deficient
animals, loss of adhesive signals would result in an inhi-
bition of cell proliferation. To address directly whether
the adhesive failure of VYS mesoderm vascular tissues
observed in SRF-null Tie2Cre
+/0·Srf
f/f yolk sac affected
proliferation, we assayed the proliferative status of VYS
mesoderm cells by BrdU labeling. Timed-pregnant mice
at E10.5, E11.5 and E12.5 were treated with BrdU 2-3
hours prior to harvesting embryonic VYS tissues. An
anti-BrdU antibody was used to detect the presence of
BrdU in nuclei of cells in S phase. BrdU-positive nuclei
were counted and results expressed as a percentage of
total nuclei detected as before. Surprisingly, we found
proliferating cells in both wild-type and SRF-null VYS
mesoderm for all time-points examined (see Figure 7).
All BrdU-positive cells detected in wild-type tissues also
expressed SRF, although most SRF-positive cells were
not positive for BrdU demonstrating that SRF expres-
sion alone is not sufficient for proliferation. As shown
in Figure 7 wild-type VYS mesoderm cells exhibit a
decrease in proliferation from E10.5 to E12.5; however,
SRF-null VYS mesoderm did not follow this same pat-
tern, showing instead a sustained rate of proliferation.
This difference was first observed at E10.5 (21 ± 1%
WT vs. 24 ± 5% Tie2Cre
+/0·Srf
f/f; p = NS), reached sta-
tistical significance by E11.5 (15 ± 2% WT vs. 22 ± 3%
Tie2Cre
+/0·Srf
f/f;p=0 . 0 3 ) ,a n dr e m a i n e dd i v e r g e n ta t
E12.5 (13 ± 2% WT vs. 22 ± 2% Tie2Cre
+/0·Srf
f/f;p=
0.005). Cells with BrdU-positive nuclei were visible
throughout E12.5 VYS mesoderm despite the complete
lack of SRF by this time-point. Furthermore, the few
remaining SRF-positive cells at E12.5 were all BrdU-
positive, even though the vast majority of BrdU-positive
cells lacked SRF. It is important to note that the non-
nuclear staining observed within the brush-border of the
VYS endoderm is a result of anti-mouse secondary anti-
body detection of maternofetally transferred IgG mole-
cules [55,56]. This phenomenon is confined to the VYS
endoderm that functions, in part, to take up IgG mole-
cules secreted into the uterine lumen. No such non-
nuclear staining is detected within the VYS mesoderm
that is the focus of our analysis. The aberrant prolifera-
tion observed in mutant VYS using BrdU analysis was
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histone H3 (PhH3) detection to assess proliferation (see
Additional File 3). PhH3 is a marker for the heavily
phosphorylated form of histone H3 associated with cells
in metaphase, and is lost as cells exit the cell cycle. In
contrast, BrdU incorporation may be found in DNA
synthesized as cells enter the cell cycle, indicating both
current and accumulated proliferation since the time of
BrdU administration. To verify that these cells were
SRF-deficient owing to Tie2-Cre-mediated recombina-
tion, we also stained these tissues for eYFP to detect
effective Cre recombinase activity (see Figure 8). We
found that BrdU-positive cells in Tie2Cre
+/0·Srf
f/f VYS
mesoderm also expressed eYFP, indicating that their
SRF-null status was due to Tie2-Cre-mediated genomic
recombination. TIE2 along with VE-Cad have been used
extensively to label VECs owing to their restricted
expression patterns. VE-Cad is an endothelial-specific
Figure 7 SRF-null VYS mesoderm tissues show aberrant proliferation. Immunodetection of BrdU incorporation was used to determine the
proliferation status of VYS tissues. Double-label immunofluorescence images of VYS tissue from wild type (A, B) and SRF-null (C, D) embryos at
E12.5. Tissues were stained for SRF (green), BrdU (red), and DNA (blue); monochrome images in B and D show BrdU staining in isolation. Arrows
in A and B highlight SRF-positive nuclei that colocalize with BrdU; arrowheads in C and D mark nuclei lacking SRF that stain positively for BrdU.
Dashed line indicates division between Ed and Md layers. Magnification = 200×, scale bar = 50 μm; Ed = endoderm, Md = mesoderm. (C)
Cytometric analysis of BrdU-positive nuclei in E10.5, E11.5 and E12.5 VYS mesoderm. Values are expressed as a percentage of total DAPI-stained
nuclei counted. *p = 0.025; **p = 0.007.
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(for review see [57], while TIE2 is a tyrosine kinase
receptor for the angiopoietin family of vascular signaling
molecules and is expressed by endothelial cells as well
as some hematopoietic progenitor cells in early develop-
ment [58]. Our staining of VYS mesoderm with the
endothelial-specific marker VE-Cad confirms the
endothelial nature of these proliferative SRF negative
cells (See Figure 3A). Taken together with Tie2Cre-
excised eYFP expression, the detection of these endothe-
lial markers throughout the VYS mesoderm demonstrate
that all proliferative cells detected are endothelial in
nature.
To assess the possibility that SRF-null cells were not
being detected due to apoptotic loss, we also assayed
SRF-null and wild-type littermate VYS tissues using
terminal deoxynucleotide transferase dUTP nick end
labeling (TUNEL). Tie2Cre
+/0·Srf
f/f VYS tissues stained
using TUNEL did not show any consistent differences
in the level of apoptosis between wild-type and SRF-null
tissues, (see Additional File 4), strongly suggesting that
the vascular failure observed in SRF null embryos is not
due simply to loss of cells in developing VYS.
Discussion
VYS is comprised of two layers: a mesoderm-derived
layer of narrow elongated cells and an endoderm-
derived layer of brush border-presenting columnar
epithelial cells. VYS mesoderm generates blood cell and
vascular precursors within blood islands by E7.5 [59],
followed by expansion and maturation of the VYS vas-
cular tree by E13.5. Angiogenic remodeling of initial
blood vessels into a mature and efficient vascular plexus
requires the orchestration of EC migration, proliferation
and apoptosis. Once blood flow begins, hemodynamic
stresses cause alterations in adhesion molecule expres-
sion profiles and EC function, ultimately leading to ves-
sel rearrangement. These processes depend heavily upon
a n di nt u r np r o f o u n d l ya f f ect cellular adhesion, both
with other cells and the surrounding matrix (see Figure
9). EC-ECM contact occurs at FAs that consist of integ-
rin receptor pairs and associated intracellular factors.
FN1 is a prominent component of the ECM surround-
ing developing vessels, and it serves as a ligand for the
a5b1-integrin receptor pair on EC [60]. FN1-mediated
activation of a5b1 leads to the induction of focal adhe-
sion kinase (FAK) signaling pathways including Src
Figure 8 Tie2Cre-mediated eYFP expression indicates BrdU-positive cells are endothelial. E12.5 VYS mesoderm tissues from
Tie2Cre
+/0·Srf
f/f embryos are virtually devoid of SRF protein yet continue to proliferate. Double-label immunofluorescence images of E12.5 VYS
from Tie2Cre
+/0·Srf
f/f·ROSA26R-eYFP
+/+ embryos. Tissues were stained for GFP (green), BrdU (red), and DNA (blue); monochrome images show
anti-BrdU (B) and anti-GFP (C) staining in isolation. Arrows mark individual BrdU-positive cells in VYS mesoderm also expressing eYFP.
Magnification = 400×, scale bar = 20 μm; Ed = endoderm, Md = mesoderm.
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Page 9 of 15recruitment, PI3 kinase induction, Raf/MEK/ERK
induction and NF-B activation (reviewed in [61]. FA
proteins such as VCL link a5b1 receptor pairs intracel-
lularly with the actin cytoskeleton [51], allowing for
transduction of extracellular signals that impose on
actin dynamics. Cell-cell contact between EC occurs at
A Ja n dT Jc o m p o s e do fV E - C a dh o m o d i m e r sa n d
CLDN5 transmembrane proteins, respectively [62].
Both VE-Cad and CLDN5 are EC-specific components
of cell-cell adhesive contacts. Each junction type
includes intracellular partners that transduce signals
caused by extracellular events. These include catenin
proteins a-a n db-catenin (CTNNA, CTNNB1) in the
case of VE-Cad, and ZO-1 associated with CLDN5.
Furthermore, activation of integrin-mediated Src signal-
ing results in disruption of VE-Cad-associated AJ, add-
ing to the complex interconnected nature of cellular
adhesion [63]. Collectively, the signaling pathways
initiated at junctional complexes act to balance the
control of cellular proliferation as well as migration
(Figure 9). Loss of proteins along these signaling cas-
cades may result in unintended cellular quiescence or
uncontrolled proliferation.
Examination of the Tie2-Cre-mediated knockdown of
SRF in VYS mesoderm has provided evidence to support
a significant role for SRF in endothelial cell function.
Previous work demonstrated that endothelial-specific
ablation of SRF protein in mice resulted in loss of vas-
cular integrity and function within VYS and ultimately
caused embryonic death by mid-gestation [36]. Our cur-
rent studies suggest that failure of SRF-null VYS tissues
and subsequent vascular failure of embryos is due to
disrupted junction complexes and junction-related sig-
naling molecules in endothelial cells of the VYS meso-
derm. Our observation that loss of SRF leads to
alterations in cell contact proteins is consistent with
previous reports in other cell types. Embryonic stem
cells lacking SRF are unable to form FA or bind appro-
priately with extracellular matrices [43,64]. Studies in
epithelial cells have verified a need for SRF in establish-
ing cell-cell contacts in developing epidermis [24]. Var-
ious studies suggest that this effect is dependent at least
in part on SRF’s ability to regulate actin dynamics,
including those necessary for formation and mainte-
nance of adhesive contacts. Actin filaments link with FA
via integrin-associated proteins such as a-actinin, talin,
and VCL, providing adhesion-related cellular input and
subsequent modulation of cell shape, motility, survival
and proliferation [65]. Our results demonstrating a lack
of VCL in SRF-null tissues strongly suggest that FAs are
unable to connect with the actin cytoskeleton appropri-
ately, resulting in impaired FA-dependent signaling.
Figure 9 Loss of SRF results in contact deficiency. Graphic highlighting the adhesive contacts involved in VYS function and signaling
between endoderm and mesoderm tissues. Molecules affected by the loss of SRF have been marked by a red “X” (B). Extracellular matrix (ECM)
containing fibronectin-1 (FN1) provides structural support and signal induction via interactions with integrins (ab ) at focal adhesions (FA). FN1 is
deposited into the ECM in by the mesoderm in response to autocrine transforming growth factor b (TGFb) signals induced by retinoic acid (RA)
released by the endoderm. FAs link intracellularly with the actin cytoskeleton via vinculin (VCL) and to signal cascades such as focal adhesion
kinase (FAK). Adherens junctions (AJ) containing vascular endothelial cadherins (VE-Cad, CDH5) and tight junctions (TJ) consisting of claudin 5
(CLDN5) molecules provide cell-cell contacts. PECAM1 molecules provide additional intercellular contacts. Nuclear localized SRF responds to actin
dynamics via interactions with MAL when released from monomeric actin. Vascular endothelial growth factor (VEGF) signals via Flk-1 to induce
ERK1/2-mediated SRF-dependent proliferation. TJP1 = tight junction protein 1, a.k.a. ZO1; a-Cat = a-catenin, CTNNA1; b-Cat = b-catenin, CTNNB1;
PXN = paxillin; RAR1/2 = RA receptors 1, 2; TGFbRI/II = TGFb receptors I, II.
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protein patterns and mRNA expression levels in SRF-
null VYS tissues. Expression of VCL and other FA mole-
cules such as tropomyosin is regulated by SRF and
MRTFs through a Rho/MAL-dependent mechanism
[17]. Furthermore, the Vcl gene has a predicted SRE
binding element [50], raising the likelihood that SRF
directly controls Vcl expression in VYS tissues. Dis-
rupted Vcl expression causes perturbations in integrin-
actin signaling as well as decreased FAK signaling [43].
Acta2 is regulated by SRF, and its loss likely contributes
to the defect generated by disrupted VCL, compounding
the mis-regulation of SRF-dependent actin dynamics.
Our study did not detect significant disruption of Itga5
expression despite the presence of a predicted SRE in
the Itga5 gene [50], perhaps indicating that Itga5 is not
under SRF regulatory control in VYS tissues. Addition-
ally, there is no evidence to suggest Fn1 is under direct
regulation by SRF. However, we observed substantial
loss of FN1 in ECM of SRF-null VYS tissues, suggesting
defects in either the transmission of extracellular signal-
ing or in ECM maintenance. VYS endoderm signals to
VYS mesoderm through a retinoic acid-transforming
growth factor b1( T G F b1) dependent pathway [66], and
chimaeric mice lacking functional TGFb receptors show
deficient deposition of FN1 between the VYS endoderm
and mesoderm layers [67]. Our observed loss of FN1
protein was accompanied by a slight decrease in Tgfb1
expression (data not shown), highlighting the require-
ment of this signaling cascade for proper VYS develop-
ment and subsequent vascular integrity. Furthermore,
FN1 deposition and maintenance depends on appropri-
ate FA signaling. The lack of intracellular VCL we
observed in SRF-null VYS tissues suggests that impaired
FA signaling contributes to the loss of extracellular FN1
[68]. Our observation of decreased VE-Cad and CLDN5
proteins suggests that AJ and TJ functions are also
impaired. VE-Cad associated with AJ has been demon-
strated to mediate contact inhibition of EC proliferation
[69]. CLDN5 has not been shown to act on cell cycle
progression; however, expression of CLDN5 is at least
in part regulated by VE-Cad [70], and suggests that TJ
act along with AJ to stabilize EC intracellular adhesion.
Our analysis also revealed that SRF-null VYS endothelial
cells have impaired proliferative control, and, in contrast
to cells in wild-type VYS, fail to downregulate prolifera-
tion. This is consistent with a model in which, during nor-
mal development, adhesive contacts and associated signal
pathways balance proliferative signals, but that loss of SRF
leads to disruption of inhibitory pathways and uncon-
trolled proliferation (see Figure 10). Our observed loss of
VE-Cad is consistent with a loss of the proliferative con-
trol conferred by AJ-mediated signaling. It should be
pointed out that our model does not posit that SRF serves
as a direct inhibitor of proliferation genes, but rather that
in some cell types, such as VYS mesoderm endothelial
cells, inhibitory pathways are modulated by SRF. Further-
more, unlike in some other cell types, our data provides
strong evidence that these cells do not require SRF protein
for proliferation, implying utilization of non-SRF-depen-
dent pathways for proliferation.
Given results presented here that SRF-null VYS
endothelial cells continue to proliferate, it seems likely
that these cells do not require SRF to proliferate even in
wild-type tissues. Numerous cell types have demon-
strated a dependence on SRF-driven IEG expression for
proliferation, including fibroblasts [27] and cells of myo-
genic lineage [28]. However, few cell types are known to
proliferate without SRF, among them mouse embryonic
stem cells [64]. Recently, Koegel and colleagues [71]
found that hyperproliferative skin cells down-regulate
SRF expression, suggesting that there may be multiple
cell types that use alternative non-SRF dependent path-
ways to regulate proliferation. They also observed
defects in both cell-cell and cell-matrix adhesive con-
tacts, suggesting that these phenomena are likely inter-
related. Furthermore, recent studies of SRF-null
hematopoietic stem cells (HSC) demonstrate that they
also exhibit cell-cell and cell-matrix adhesion failure,
that this failure is due to impaired integrin-related sig-
naling, and that HSC proliferation is not negatively
affected by the loss of SRF [72]. These observations are
consistent with our model where SRF acts as a modula-
tor of cell-cell and cell-matrix adhesion molecules that
indirectly affect proliferation due to a loss of adhesion-
mediated inhibition. Down-regulation of SRF in this
context allows modulation of adhesive integrity and
associated actin-dependent junction maintenance neces-
sary for cellular proliferation and migration; however,
SRF-independent proliferation of cells within the VYS
mesoderm that is required for angiogenic remodeling
remains functionally intact.
Figure 10 Model for how loss of SRF-dependent adhesion
molecules leads to increased proliferation. (A) Adhesion-
mediated signaling pathways associated with control of
proliferation. SRF regulated molecules are shown in grey boxes. (B)
Molecules downregulated by the loss of SRF have been faded and
marked by an “X”. AJ = adherens junction; FA = focal adhesion; TJ =
tight junction (see text for further discussion).
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Our study provides evidence to suggest that the role of
SRF in proliferation is balanced with its role in actin-
dependent junction dynamics. It remains to be deter-
mined which junction proteins are affected through direct
SRF-mediated transcriptional regulation and which may
be dependent on SRF-related actin dynamics for proper
function. The intimacy between the actin cytoskeleton
and membrane bound adhesion molecules provides a
broad reach for SRF to respond to signaling that initiates
at the plasma membrane. Our results demonstrating that
loss of cellular adhesive contacts results in impaired pro-
liferative control is consistent with previous studies; how-
ever, we show for the first time evidence that VYS
mesoderm endothelial cells do not require SRF for prolif-
eration. Further study will be necessary to determine
which proliferative pathway dominates in these cells.
Methods
Mice and genotyping
Tie2-Cre
+/0 and Srf
f/f mice have been described previously
[39,40]. The ROSA26R-eYFP
+/+ (stock #006148) and
ROSA26R-bGal
+/+ (stock #003310) reporter mouse strains
were purchased from the Jackson Laboratory. Embryos
were generated by timed mating, designating noon on the
day a vaginal plug was observed as embryonic day 0.5
(E0.5). Genotyping was performed using standard proto-
cols utilizing genomic DNA isolated from embryonic yolk
sac, amnion or tail tissue. Primers used were: Tie2-Cre
+/0
fwd 5’-GTTCGCAAGAACCTGATGGACA-3’ and rvs
5’-CTAGAGCCTGTTTTGCACGTTTC-3’; Srf
f/f fwd 5’-
TGCTTACTGGAAAGCTCATGG-3’ and rvs 5-’TGCT
GGTTTGGCATCAACT. ROSA26R-eYFP mice were gen-
otyped according to protocols from Jackson using the fol-
lowing three primers: WT-fwd 5’-GGAGCGGGAGA
AATGGATATG-3’,e Y F Pf w d5 ’-AAGACCGCGAA-
GAGTTTGTC-3’, and rvs 5’-AAAGTCGCTCTGAGTTG
TTAT-3’. ROSA26R-bGal
+/+ mice were genotyped accord-
ing to protocols from Jackson using the following three
primers: F150 fwd 5’-GGCTTAAAGGCTAACCT-
GATGTG-3’,T gr v s5 ’-GCGAAGAGTTTGTCCT-
CAACC-3’,a n dW T - r v s5 ’-GGAGCGGGAGAAATG
GATATG-3’. Animals designated for BrdU incorporation
studies were administered BrdU Labeling Reagent by
intraperitoneal injection (dose 1 mL/100 g body weight;
Invitrogen 00-0103) and harvested for tissues after 2-4
hours. All procedures were in compliance with the Institu-
tional Animal Care and Use Committee of the Medical
College of Wisconsin.
Histology and imaging
Embryos were harvested from timed pregnant females,
and yolk sac tissues were dissected and fixed in either
Tris-buffered zinc fixative (0.1 M Tris pH7.4 with 3.2
mM calcium acetate, 22.8 mM zinc acetate, and 36.7
mM zinc chloride) or zinc formalin (Richard-Allan
Scientific). Samples were processed for paraffin embed-
ding, and sections (5-7 μm) were used for immunofluor-
escence histochemistry as described [36,73]. Reagents
used were: anti-serum response factor (SRF; Protein-
Tech custom); anti-smooth muscle a-actin (ACTA2;
Sigma, clone 1A4); anti-integrin a5 (ITGA5; Millipore,
AB1921); anti-fibronectin (FN1; Millipore, AB2033);
anti-vinculin (VCL; abcam, ab18058); anti-BrdU (Invi-
trogen, 03-3900); anti-Histone H3, phosphorylated form
(PhH3; Millipore 06-570); anti-vascular endothelial cad-
herin (CDH5, a.k.a. VE-Cad; abcam 33168); anti-epithe-
lial cadherin (CDH1, a.k.a. E-Cad; BD Biosciences
610181). eYFP protein was detected using anti-GFP anti-
body (Invitrogen, A10262). Anti-ACTA2 antibody clone
1A4 detects a-actin found in several cell types, and was
not used as a specific SMC label. DNA/nuclei were
counterstained with DAPI. Terminal deoxynucleotide
transferase dUTP nick end labeling (TUNEL) was per-
formed on zinc formalin fixed paraffin-embedded 5 μm
sections using the DeadEnd Colorimetric Apoptosis
Detection System (Promega); DNase-treated wild-type
VYS tissue was used as a positive control according to
detection system protocol. Tissues harvested for detec-
tion of Tie2-Cre-associated b-galactosidase activity were
fixed in 4% paraformaldehyde and LacZ stained under
standard protocols. Digital image capture was performed
using a Nikon Eclipse 80i microscope equipped with
Nikon Digital Sight DS-2MBW monochrome and DS-F1
color cameras and NIS Elements-D imaging software.
Tri-color image merge and post-processing was done in
Adobe Photoshop CS4.
Cytometric analysis
Thin sections (5 μm) of embryonic yolk sac from wild-
type and Tie2Cre
+/0·Srf
f/f embryos were stained for
designated markers and imaged for cell counting. Posi-
tive nuclear staining was scored only in cells of the
mesoderm layer of the visceral yolk sac. Between 300-
500 nuclei over 5 visual fields (1 per section; 200× mag-
nification) were counted for each embryo, with a total
of 3 embryos per treatment group; embryos were taken
from 2-3 different litters harvested on different days.
Tissues were stained for SRF protein to verify loss of
expression in BrdU treated tissues. Anti-BrdU antibody
was used to detect incorporation into nuclear material
of proliferating cells; PhH3 was used to label cells
undergoing mitosis. Detection of ACTA2 protein was
used to verify loss of Srf expression in PhH3 stained tis-
sues due to incompatibility between anti-PhH3 and anti-
SRF antibodies. DAPI was useda sc o u n t e r - s t a i na n dt o
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ing positive for SRF, BrdU or PhH3 were expressed as a
percentage of total number of DAPI-positive nuclei
counted.
Real-time quantitative PCR (qPCR) and analysis
Embryos were harvested from timed pregnant females,
and yolk sac tissues were dissected and processed for
RNA (Qiagen RNeasy Mini Kit) and cDNA template
(SABiosciences RT
2 First Strand Kit C-03) using pub-
lished protocols. Samples were probed using SYBR
Green with ROX reference (SABiosciences RT
2 Real-
Time SYBR Green/Rox Master Mix PA-012) using 100
nm primer oligos under published protocols in a Strata-
gene Mx3005P Real-Time PCR System. Wild type and
Tie2Cre
+/0·Srf
f/f whole VYS tissues (n = 3 each) were
assayed separately using 100 ng template per reaction.
Differences between wild type and SRF null tissues were
calculated using the 2^ΔΔCt method based on the
Guide to Performing Relative Quantitation of Gene
Expression Using Real-Time Quantitative PCR (Applied
Biosystems) with all genes normalized to Gapdh expres-
sion. Data is presented as fold change with positive SEM
only owing to the asymmetrical nature of confidence
intervals in exponential fold change calculations. See
Additional File 5 for real-time qPCR primer sequences.
Additional material
Additional file 1: Tie2-Cre expression is restricted to VYS mesoderm.
Color photomicrographs of Lac-Z stained VYS tissues from Tie2-Cre
+/0
·ROSA26R-bgal
+/+ embryos in whole mount (A & B) and cross-sectional (C
& D) views. We used ROSA26R-b-galactosidase reporter transgenic mice to
examine the lineage distribution pattern of cells affected by Tie2-Cre
recombinase activity. The Tie2-Cre construct begins expressing at E7.5 in
endothelial cells and hematopoietic progenitor cells within blood islands
of the visceral yolk sac (VYS) mesoderm where it remains until 9.5.
Examination of whole mount tissues revealed robust signal in major
vessels of VYS at E10.5 (A, arrow). By E12.5 this signal is widespread in
VYS mesoderm (B, arrow). Cross-sectional analysis of VYS tissues at E10.5
(C) and E12.5 (D) demonstrate the strict confinement of Lac-Z signal to
VYS mesoderm. Magnification C & D = 200×; scale bar D = 100 μm. Ed =
endoderm, Md = mesoderm, * = blood vessel lumen.
Additional file 2: ACTA2 expression is disrupted prior to complete
loss of SRF. Double-label immunofluorescence analysis of SRF and
ACTA2 expression in wild type (A & C) and Tie2Cre
+/0·Srf
f/f (B & D)
embryos at E10.5 and E11.5. Expression of ACTA2 is SRF-dependent and
is apparent in wild-type visceral yolk sac tissues by E10.5 (A), and remains
strong at E11.5 (C) and E12.5 (see Figure 2A). This robust level of protein
decreases noticeably in SRF-null tissues by E10.5 when SRF levels are low
but still detectable(B), suggesting that ACTA2 expression is acutely
sensitive to regulation by SRF. Further decrease is observed at E11.5 (D).
Magnification = 200×; scale = 50 μm. Ed = endoderm, Md = mesoderm.
Additional file 3: PhH3 analysis indicates SRF-null VYS mesoderm
tissues show aberrant proliferation. Immunodetection of PhH3 was
used to assess proliferation in VYS mesoderm tissues. Double-label
immunofluorescence images of VYS tissue from wild type (A, B) and SRF-
null (C, D) embryos at E12.5. Tissues were stained for PhH3 (green),
ACTA2 (red), and DNA (blue); monochrome images in B and D show
PhH3 staining in isolation. Arrows in A and B highlight SRF-positive
nuclei that colocalize with PhH3; arrowheads in C and D mark nuclei
lacking SRF that stain positively for PhH3. Dashed line indicates division
between Ed and Md layers. Magnification = 200×, scale bar = 50 μm; Ed
= endoderm, Md = mesoderm. (C) Cytometric analysis of PhH3-positive
nuclei in E10.5, E11.5 and E12.5 VYS mesoderm. Values are expressed as a
percentage of total DAPI-stained nuclei counted. *p = 0.00005; **p =
0.025.
Additional file 4: Loss of SRF in VYS mesoderm does not alter the
level of apoptosis. Colorimetric TUNEL analysis in wild type (A) and
Tie2Cre
+/0·Srf
f/f (B) VYS tissues at E12.5 to detect DNA damage caused by
apoptosis. DNase treatment of wild-type E12.5 VYS tissue was used as a
positive control (C). We did not observe differences in the rate of
apoptosis between wild-type and SRF-null tissues. Magnification = 200×,
scale = 100 μm. Ed = endoderm, Md = mesoderm.
Additional file 5: Primers for qPCR. Two independently published sets
of qPCR primers for the Ilk gene were used in our analysis. Neither set
generated any signal in any VYS tissue we assayed. Primer sets were
tested for specificity against HeLa cell cDNA and successfully detected
appropriate signal.
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